NICE to take longer on kidney anticancers
This article was originally published in Scrip
Executive Summary
The UK's National Institute for health and Clinical Excellencehas extended until January its assessment of four kidney cancer drugs, none of which was deemed cost-effective in a draft appraisal issued in August (Scrip Online, August 8th, 2008).